Drug Profile
Treprostinil palmitil - Insmed
Alternative Names: C16-TR; INS-1009; Nebulised treprostinil palmitil - Insmed; Nebulised treprostinil prodrug - Insmed; TPIP; TPIS - Insmed; Treprostinil palmitil inhalation powder - Insmed; Treprostinil palmitil inhalation suspension - InsmedLatest Information Update: 01 Mar 2024
Price :
$50
*
At a glance
- Originator Insmed
- Class Acetic acids; Antifibrotics; Antihypertensives; Cyclopentanes; Naphthalenes; Prostaglandins; Skin disorder therapies; Small molecules; Vasodilators
- Mechanism of Action Epoprostenol receptor agonists; Platelet aggregation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II/III Pulmonary arterial hypertension; Pulmonary hypertension
- Phase I Idiopathic pulmonary fibrosis
Most Recent Events
- 31 Dec 2023 Insmed has patent protection for treprostinil palmitil in USA
- 30 Nov 2023 Insmed completes enrolment in its phase II trial for Pulmonary hypertension in Argentina, Belgium, Italy, Germany, Puerto Rico, Spain and in the US, UK, Australia, New Zealand (Inhalation, Powder) (NCT05176951)
- 26 Oct 2023 Adverse events data from a phase II trial in Pulmonary hypertension released by Insmed